-
Product Insights
Low-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Low-Grade Glioma - Drugs In Development, 2023’, provides an overview of the Low-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Low-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enavogliflozin in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enavogliflozin in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enavogliflozin in Type 2 Diabetes Drug Details: Enavogliflozin (Envlo) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vaccine For Glioma in Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vaccine For Glioma in Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Vaccine For Glioma in Glioma Drug Details:The vaccine candidate (PEPIDH1M) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAGE-718 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAGE-718 in Parkinson's Disease report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Refractory Multiple Myeloma Drug Details: Nivolumab (Opdivo, Opdyta) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine for Glioma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Vaccine for Glioma Drug Details The vaccine candidate (PEPIDH1M) is under development for the...
-
Product Insights
Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Recurrent Medulloblastoma Global Clinical Trials Review, H1, 2018" provides an overview of Recurrent Medulloblastoma clinical trials scenario. This report provides top line data relating to the clinical trials on Recurrent Medulloblastoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...